

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 38602/1329
Prior Application Serial No.: 09/322,297
Prior Application Filing Date: 5/28/1999
Applicant: Peng Cho Tang, et al.

(Use several sheets if necessary)

11002 U.S. PTO
10/081147

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
DMW	A1	4,053,613	10/11/77	Rovnyak et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

Donna Wright

DATE CONSIDERED

6-11-03

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
snw	B1	3,308,134	03/07/67	Plostnieks, Janis			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
snw	B2	99/61422	21/02/99	WO				
snw	B3	99/48868	09/30/99	WO				
snw	B4	98/24432	06/11/98	WO				
snw	B5	98/38984	09/11/98	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

snw	B6	Sun, et al. "Design, Synthesis, and Evaluation of Substituted 3-[(3-or 4-Carbonxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," J. Med. Chem. 42:5120-5130 (1999) ©American Chemical Society
	B7	Database CAPLUS, AN 1998: 151222, abstract for MOHAMMADI et al., Crystal structures of a protein-tyrosine kinase, WO 98/07835 (February 26, 1998).
snw	B8	Database CAPLUS on STN, AN 1998: 147306, abstract for TANG et al., Indolinone combinatorial libraries and related products and methods for the treatment of disease, WO 98/07695 (February 26, 1998).
snw	B9	Database CAPLUS on STN, AN 1997: 140244, abstract for Tang et al., Indolinone compounds capable of modulating tyrosine kinase signal transduction, WO 96/40116 (December 19, 1996).

EXAMINER

Sonya Wright

DATE CONSIDERED

6-11-03

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	European Search Report of 99927120

EXAMINER

Danya Wright

DATE CONSIDERED

6-11-03

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
DNW	AA	Re. 36,256	7/20/99	Spada et al.	514	249	12/10/97

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	AB	99/10325	04.09.99	WO/PCT (McNutt et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER:

Donya Wright

DATE CONSIDERED:

6-16-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, *et al.*

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>SNW</i>	AA	5,217,999	6/8/93	Levitzki et al.	514	613	3/24/92
<i>SNW</i>	AB	5,302,606	4/12/94	Spada et al.	514	357	4/16/91
<i>SNW</i>	AC	5,330,992	7/19/94	Eissenstat et al.	514	312	10/23/92

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>SNW</i>	AD	91/15495	17.10.91	WO/PCT (Dow et al.)				
<i>SNW</i>	AE	92/20642	26.11.92	WO/PCT (Spada et al.)				
<i>SNW</i>	AF	92/21660	10.12.92	WO/PCT (Dow)				
<i>SNW</i>	AG	0 566 226 A1	20.10.93	EP (Barker et al.)				
<i>SNW</i>	AH	94/03427	17.02.94	WO/PCT (Dobrusin et al.)				
<i>SNW</i>	AI	94/14808	07.07.94	WO/PCT (Buzetti et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>SNW</i>	AJ	Akbasak et al., "Oncogenes: cause of consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)
<i>SNW</i>	AK	Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989)
<i>SNW</i>	AL	Arvidsson et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994)
<i>SNW</i>	AM	Baserga, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994)
<i>SNW</i>	AN	Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)
<i>SNW</i>	AO	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)
<i>SNW</i>	AP	Bolen, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993)

EXAMINER:

Donna Wright

DATE CONSIDERED:

6-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DNW	AQ	Bonner et al., "Structure and Biological Activity of Human Homologs of the <i>raf/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985)
DNW	AR	Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993)
DNW	AS	Claesson-Welsh, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994)
DNW	AT	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994)
DNW	AU	De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)
DNW	AV	Decker et al., "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>Journal of Immunological Methods</u> 15:61-69 (1988)
DNW	AW	Dickson et al., "Tyrosine kinase receptor -- nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992)
DNW	AX	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992)
DNW	AY	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989)
DNW	AZ	Fingl and Woodbury, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975)
	BA	Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," <u>Kidney International</u> 43:S47-S54 (1993)
DNW	BB	Folkman and Shing, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992)
DNW	BC	Folkman, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)
DNW	BD	Folkman, "Tumor Angiogenesis, Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)
DNW	BE	Folkman, "What is evidence that tumors are angiogenesis dependent?" <u>Journal of National Cancer Institute</u> 82:4-6 (1990)
DNW	BF	Gennaro (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)
DNW	BG	Goldring and Goldring, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)
DNW	BH	Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987)

EXAMINER:

Danya Wright

DATE CONSIDERED:

6-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, *et al.*

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

QNW	BI	Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992)
QNW	BJ	Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12(3):981-990 (1992)
QNW	BK	Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)
QNW	BL	Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cy1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993)
QNW	BM	Kashishian et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11(4):1373-1382 (1992)
QNW	BN	Kazlauskas et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syt," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)
QNW	BO	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)
QNW	BP	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)
QNW	BQ	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992)
QNW	BR	Klagsbrun and Soker, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993)
QNW	BS	Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)
QNW	BT	Komada and Kitamura, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)
QNW	BU	Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992)
QNW	BV	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983)
QNW	BW	Kumabe et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)
QNW	BX	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118:1057-1070 (1992)

* reference initialed in the PTO-1449 filed 7-24-03.

EXAMINER:

Sonya Wright

DATE CONSIDERED:

6-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DNW	BY	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Research</u> 50:2511-2517 (1990)
	BZ	Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)
DNW	CA	Millauer et al., "High Affintiy VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993)
	CB	Morrison et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988)
DNW	CC	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983)
DNW	CD	Nishimura et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)
DNW	CE	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)
DNW	CF	Quinn et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)
DNW	CG	Rozakis-Adcock et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)
DNW	CH	Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)
DNW	CI	Sandberg-Nordqvist et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)
DNW	CJ	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992)
DNW	CK	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <u>Oncogene</u> 5:519-524 (1990)
DNW	CL	Slamon et al., "Studies of the HER-2/ <i>neu</i> Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)
DNW	CM	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993)
DNW	CN	Songyang et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994)
DNW	CO	Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech</u> 14:600-605 (1996)

EXAMINER:

Sonya Wright

DATE CONSIDERED:

6-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

QNW	CP	Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993)
QNW	CQ	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)
QNW	CR	Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>AMPIS</u> 100:713-719 (1992)
QNW	CS	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)
QNW	CT	Twamley-Stein et al., "The Src family tyrosine kinases are required for platelet-derived-growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci.</u> 90:7696-7700 (1993)
QNW	CU	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990)
QNW	CV	Voller et al., "Ch. 45 - Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980)
QNW	CW	Weidner et al., "Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma," <u>New England Journal of Medicine</u> 324(1):1-8 (1991)
QNW	CX	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)

SI-17746.1

EXAMINER:

Douglas Wright

DATE CONSIDERED:

6-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	4,002,749	01-11-77	Rovnyak	424	246	08-12-75
	AB	4,966,849	10-30-90	Vallee et al.	435	199	2-2-89
<i>DMW</i>	AC	5,217,999	06-08-93	Levitzki et al.	514	613	3-24-92
	AD	5,302,606	04-12-94	Spada et al.	514	357	4-16-91
	AE	5,330,992	07-19-94	Eissenstat et al.	514	312	10-23-92
	AF	5,786,488	07-28-98	Tang	548	455	11-5-97
	AG	5,792,783	08-11-98	Tang	514	397	6-5-96
	AH	5,840,745	11-24-98	Buzzetti	514	414	12-22-95
	AI	5,880,141	03-09-99	Tang	514	339	6-7-95
	AJ	5,883,113	03-16-99	Tang	514	418	6-5-96
	AK	5,883,116	03-16-99	Tang	514	418	6-5-98
	AL	5,886,020	03-23-99	Tang	514	418	6-6-96
<i>DMW</i>	AM	Re 36,256	07-20-99	Spada et al.	514	249	12-10-97

FOREIGN PATENT DOCUMENTS

EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLAT YE NO
<i>DMW</i>	AN	91-13055	09-05-91	WO-PCT (Buzzetti et al.)			
<i>DMW</i>	AO	91-15495	10-17-91	WO-PCT (Dow et al.)			
	AP	92-07830	05-14-92	WO-PCT (Nakanishi et al.)			
<i>DMW</i>	AQ	92-20642	11-26-92	WO-PCT (Spada et al.)			
<i>DMW</i>	AR	92-21660	12-10-92	WO-PCT (Pfizer)			
	AS	93-23040	11-25-93	WO-PCT (Merck)			
<i>DMW</i>	AT	94-03427	02-17-94	WO-PCT (Dobrusin et al.)			

EXAMINER:

Donya Wright

DATE CONSIDERED:

6-11-03

XAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include a copy of this form with next
communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

	AU	84-10202	05-11-94	WO-PCT (Johnston et al.)				
onw	AV	94-14808	07-07-94	WO-PCT (Buzzetti et al.)				
	AW	95-24190	09-14-95	WO-PCT (Chen et al.)				
	AX	96-00226	01-04-96	WO-PCT (Buzzetti et al.)				
	AY	96-16964	06-06-96	WO-PCT (Buzzetti et al.)				
onw	AZ	96-40116	12-19-96	WO-PCT (Tang et al.)				
onw	BA	98-07695	02-26-98	WO-PCT (Tang et al.)				
	BB	98-07835	02-26-98	WO-PCT (Mohammadi)				
	BC	98-45708	10-15-98	WO-PCT (Clary)				
	BD	98-50350	11-12-98	WO-PCT (Tang et al.)				
	BE	98-56376	12-17-98	WO-PCT (Tang et al.)				
	BF	99-10325	03-04-99	WO-PCT (McNutt et al.)				
	BG	0 252 731 A1	01-13-88	EP(Howard)				
onw	BH	0 566 226 A1	10-20-93	EP (Barker)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

onw	BI	Akbasak and Sunar-Akbasak et al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)
	BJ	Andreani et al., "Synthesis and potential o anthracycline activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924(1997)
	BK	Andreani et al., "In vivo cardiotoxic activity of pyridylmethylene-2-indolinones" <u>Arzneimittel-Forschung Drug Research</u> 48(II): 727-729 (1998)
onw	BL	Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989)
	BM	Arvidsson et al., "Try-716 in the Platelet-Derived-Growth-Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994)
	BN	Baserga, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994)
	BO	Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)
	BP	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)
	BQ	Bolen, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993)
onw	BR	Bonner et al., "Structure and Biological Activity of Human Homologs of the raf-mil Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

Atty. Docket No. 88602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DNW	BS	Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993)
	BT	Carpeneo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs" <u>Analytical Biochemistry</u> 244:74-78 (1997)
	BU	Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron" <u>Chinese Journal of Physiology</u>
DNW	BV	Claesson-Welsh, "Signal Transduction by the PDGF Receptor," <u>Progress in Growth Factor Research</u> 5:37-54 (1994)
DNW	BW	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994)
	BX	Damiani et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48(6):1155-1161 (1994)
	BY	Davis et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16(9):1043-1045 (1973)
DNW	BZ	De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255: 989-991
	CA	Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988)
	CB	Dickson et al., "Tyrosine kinase receptor -- nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992)
DNW	CC	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992)
	CD	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2-neu Gene Product," <u>Cancer Research</u> 50:1550-1558 (1990) (mistakenly referred to as Fendley)
DNW	CE	Ferrara and Henzel, "Pituitary Fillicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989)
DNW	CF	Fingl and Woodbury, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975)
	CG	Floege et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangio proliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993)
DNW	CH	Folkman and Shing, "Angiogenesis," <u>J. Bio.Chem.</u> 267: 10931-10934 (1992)
	CI	Folkman, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)
	CJ	Folkman, "Tumor Angiogenesis, Therapeutic Implications," <u>New England J. Medicine</u> 285: 1182-1186 (1971)
DNW	CK	Folkman, "What Is Evidence that Tumors Are Angiogenesis Dependent?" <u>Journal of National Cancer Institute</u> 82: 4-6
	CL	Gazit et al., "Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalonitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2-neu tyrosine kinases," <u>J. Med. Chem.</u> 34(6):1896-1907 (1991)
DNW	CM	Gennaro (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)
DNW	CN	Goldring and Goldring, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)

EXAMINER:

Donya Wright

DATE CONSIDERED:

6-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, *et al.*

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
CO	Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger", <u>The Journal of Biological Chemistry</u> 268(13):9165-9168 (1993)	
<i>SNW</i> CP	Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987)	
CQ	Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Bio. Chem.</u> 267: 26031-26037	
CR	Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12(3): 981-990 (1992)	
CS	Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)	
CT	Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C γ 1," <u>Molecular Biology of the Cell</u> 4: 49-57 (1993)	
<i>SNW</i> CU	Kashishian et al., "Phosphorylation Sites in the PDGF receptor with Different Specificities for Binding GAP and PI3 Kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11(4): 1373-1382 (1992)	
CV	Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993)	
<i>SNW</i> CW	Kazlauskas et al., "The 64-kDa Protein That Associates with the Platelet-Derived Growth Factor Receptor β Subunit via Tyr-1009 Is The SH2-Containing Phosphotyrosine Phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)	
CX	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)	
CY	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)	
CZ	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992)	
DA	Klagsburn and Soker, "VEGF-VPF: The Angiogenesis Factor Found?" <u>Current Biology</u> 3:699-702 (1993)	
DB	Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)	
DC	Komada and Kitamura, "The cell dissociation and motility triggered by scatter factor-hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)	
DD	Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992)	
DE	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity ¹ ," <u>J. Immunol. Methods</u> 64:313-320 (1983)	
DF	Kumabe et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)	
<i>SNW</i> DG	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118:1057-1070 (1992)	
DH	Levitzki et al., "Tyrosine kinase inhibition: An approach to drug development," <u>Science</u> 267:1782-1788 (1995)	
DI	Maass et al., "Viral resistance to the thiazolo iso-indolines, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase", <u>Antimicrobial Agents and Chemotherapy</u> 37(12) 2612-2617 (1993)	

EXAMINER:

Dorcas Wright

DATE CONSIDERED:

6-11-03

XAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>DNW</i>	DJ	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell-lines and fresh tumor cells," <u>Cancer Research</u> 50:2511-2517 (1990)
	DK	Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:301 at abstract no. 2268 (March 1994)
<i>DNW</i>	DL	Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72: 835-846
<i>DNW</i>	DM	Mohammadi et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," <u>Science</u> 276(5314):955-960 (1997)
	DN	Moreto et al., "3,3-bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (BHMI), the active metabolite of the laxative sultisatin" <u>Arzneimittel-Forschung Drug Research</u> 29(II): 1561-1564 (1979)
	DO	Moreto et al., "Study of the laxative properties of the disodium salt of the sulfonic diester of bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (Dan-603) in the rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976)
	DP	Morrison et al., "Signal Transduction from Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increases Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85: 8855-8859
<i>DNW</i>	DQ	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983)
	DR	Nishimura et al., "Two Signaling Molecules Share a phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896
	DS	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)
	DT	Quinn et al., "Fetal Liver Kinase 1 as a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)
	DU	Rozakis-Adcock et al., "Association of the Shc and Grb2-Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692
	DV	Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)
	DW	Sandberg-Nordqvist et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)
	DX	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992)
<i>DNW</i>	DY	Shibuya et al., "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene
	DZ	Singh et al., "Indolinone derivatives as potential antimicrobial agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989)
	EA	Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprie (Azotidin 3', 4-Indol 2'-Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)
<i>DNW</i>	EB	Slamon et al., "Studies of the HER-2-neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)
<i>DNW</i>	EC	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993)
<i>DNW</i>	ED	Songyang et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps-fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994)
	EE	Spada et al., "Small Molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5(8):805-817 (1995)

EXAMINER:

Danya Wright

DATE CONSIDERED:

6-11-03

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

Atty. Docket No. 38602/1329

Prior Application Serial No.: 09/322,297

Prior Application Filing Date: 5/28/1999

Applicant: Peng Cho Tang, et al.

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AW	EF	Sun et al., "Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases," <u>J. Med. Chem.</u> 41(14):2588-2603 (1998)
	EG	Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech</u> 14:600-605 (1996)
	EH	Superti-Furga et al., "Cck inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993)
	EI	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)
	EJ	Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>AMPIS</u> 100:713-719 (1992)
	EK	Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997)
	EL	Tsai et al., "The effect of 3,3-Di-Pyridyl Methyl 1-Phenyl 2-indoline on the nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31(9):943-947 (1992)
AW	EM	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)
AW	EN	Twamley-Stein et al., "The Src Family Tyrosine Kinases are Required for Platelet-Derived Growth Factor-Mediated Signal Transduction in NIH 3T3 Cells," <u>Proc. Natl. Acad. Sci.</u> 90: 7696-7700
AW	EO	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990)
	EP	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carboxymethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989)
AW	EQ	Voller et al., "Ch. 45 - Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980)
	ER	Walker, "The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-637 (1965)
AW	ES	Weidner et al. "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma," <u>New England Journal of Medicine</u> 324(1): 1-8 (1991)
AW	ET	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)
	EU	Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-64 (1999)
	EV	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-294 (1996)

* This reference was initiated in the PTO-1449 filed 7-24-03.

EXAMINER:

Donna Wright

DATE CONSIDERED:

6-11-03

XAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;
 Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant